Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

About this update from Jaguar Health, Inc.

[{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three other members of the Company's board of directors, and seven other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase agreements, pursuant to which the Company will issue up to $3.448 million aggregate principal amount of convertible promissory notes (collectively, the "Notes") to such Investors in a private placement priced at-the-market under Nasdaq rules. The Notes will have a 3-month maturity, will bear interest at 6% per annum, and will be convertible immediately at the option of the Investors into shares of the Company's common stock.","length":904,"tagName":"p"},{"type":"text","content":"The Company will use the proceeds for working capital and other general corporate purposes. In addition, the Company has agreed to issue to the Investors unregistered warrants, which will be exercisable immediately and will expire on the earlier of (i) five years from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.","length":392,"tagName":"p"},{"type":"text","content":"The offering is expected to close on or about March 27, 2025, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.","length":205,"tagName":"p"},{"type":"text","content":"The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the convertible notes and warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with in...

More updates from Jaguar Health, Inc.